Farmak has expanded the range of own-manufactured drugs used in the treatment of glaucoma. The company began marketing Lanotan ® T eye drops, a new combination drug to treat glaucoma. The new medication includes two active ingredients – latanoprost and timolol.
As we know, glaucoma is an eye disease contracted as a result of upsetting the balance between the quantity of intraocular fluid produced by an eye and the quantity of intraocular fluid channeled into vascular system, which causes intraocular pressure to rise. Unfortunately, modern medicine cannot treat glaucoma. It may only suppress its further development using special glaucoma management medication. All glaucoma therapy eye drops need to be administered during the entire life or until surgery is made, which is not always advisable and effective. Moreover, the majority of these drops have to be administered to people with glaucoma two or three times per day, which means additional inconvenience for patients.
Olena Alekseieva, Marketing Specialist at Farmak’s Department for Marketing of Ophthalmological and Dermatological Drugs: ‘Lanotan® T is a combination drug used in glaucoma therapy, containing two active ingredients with opposite action: latanoprost and timolol. Timolol helps reduce secretion of intraocular fluid and latanoprost improves its outflow. This dual-action mechanism helps manage development of glaucoma process even in patients with glaucoma in developed and chronic phase, postponing or even substituting (in certain cases) glaucoma surgeries’.
In addition to efficacy, an unconditional advantage of Lanotan® T is a convenience of administration: only once a day at evenings, which makes it comfortable for patients and boosts inclination toward a therapy prescribed by doctor, and in the end, improves results of treatment.
The TOP 100 of the country’s most valued trademarks was presented by Novoe Vremya magazine in association with MPP Consulting. The cost of each brand was estimated by MPP Consulting. The valuation methodology is based on financial performance of brand owners, as well as factors that may influence the brand’s value, such as geographical coverage [&helli...
This edition is dedicated to Quality in all its manifestations and areas. In this edition, we discuss the following issues: How to protect oneself from drug falsification; • Where can one read about drug bioequivalence; • How are drugs disposed of; • How Farmak cares about the quality of its drugs. We remind that ‘Farmak […]
The purpose of the visit was to increase sustainability in the healthcare sector. On 15 November, Farmak welcomed the representatives of the government, non-governmental organizations, research institutes and UN system agencies within the framework of the Sustainable Procurement Workshop of the United Nations Development Programme. During the visit, the gues...